题名 | TRF-budesonide (Nefecon) positively impacts serum and urinary biomarkers involved in interstitial fibrosis in patients with IgAN: analysis from the Phase 2 NEFIGAN trial | 链接 | https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02392948/full |
https://www.cochranelibrary.com/ ... al/CN-02392948/full |